期刊
HUMAN GENE THERAPY
卷 28, 期 12, 页码 1147-1157出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2017.126
关键词
chimeric antigen receptor; CAR; adoptive cell therapy; bispecific targeting; CD19; CD20; leukemia; relapse
资金
- Deutsche Jose Carreras Leukamie-Stiftung, Munchen
- Deutsche Forschungsgemeinschaft, Bonn
- Else Kroner-Fresenius Stiftung, Bad Homburg v.d.H.
- Wilhelm Sander-Stiftung, Munchen
- Medical Faculty of the University of Cologne
The treatment of leukemia/lymphoma by chimeric antigen receptor (CAR) redirected T cells with specificity for CD19 induced complete remissions in the majority of patients, with a realistic hope for cure. However, recent follow-up data revealed a substantial risk of relapse through leukemic cells that lack the CAR targeted antigen. In this situation, a bispecific CAR with binding domains for CD19 and CD20 is aimed at recognizing leukemic cells with only one cognate antigen. The anti-CD20-CD19 bispecific CAR induced a full T-cell response upon engagement of CD19 or CD20 on target cells showing a true `` OR'' gate recognition in redirecting T-cell activation. T cells with the anti-CD20-CD19 CAR efficiently killed patients' chronic lymphocytic leukemia cells in vitro. The bispecific CAR T cells cleared pediatric acute lymphocytic leukemia with a mixed CD19+ CD20+/CD20-phenotype from the blood and bone marrow of transplanted mice, while anti-CD20 CAR T cells left CD20-leukemic cells behind without curing the disease. Data indicate the superior anti-leukemic activity in the control of leukemia, implying that the anti-CD20-CD19 bispecific CAR T cells may reduce the risk of relapse through antigen-loss leukemic cells in the long term.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据